BOD's Principal Activity is the development and manufacture of CBD and hemp products for consumer markets in Australia and United Kingdom as well as the development, manufacture and distribution of therapeutics medicinal cannabis products based on Good Manufacturing Practice (GMP) certified cannabis extracts for medical markets.
|Bid / Ask||-|
|Volume (4w avg)|
|vs Sector (1yr)||-|
|vs ASX 200 (1yr)||-65.62%|
|ASX Rank||1,617 of 2,313|
|Sector Rank||148 of 203|
Bod Australia Limited (BOD, formerly Bod Australia Limited) is a cannabis centric healthcare company.Delivering products for both the consumer markets and medical markets.
No incorporation details available.
DPS and Yield calculations use the Pay Date.
|Mr Johannes (Hanno) Jacobus Cappon||Non-Executive Director||Jul 2021||
Mr Johannes (Hanno) Jacobus Cappon
Mr Cappon has experience in biochemistry, nutrition, health and innovation. He has a background in chemistry, life sciences, nutrition and health innovation and developing new consumer and healthcare solutions for commercialization. Mr Cappon is currently Chief Technology Officer at H&H, a position which he has held since January 2021. Mr Cappon's previous senior roles with international companies include VP R&D Nutritionals & Digestive Health at Bayer Consumer Health, Switzerland, as well as VP R&D Nutricia Medical Nutrition at multinational food company Danone Nutricia, Netherlands, amongst others.
|Mr Mark Masterson||Non-Executive Director,Non-Executive Chairman||Nov 2019||
Mr Mark Masterson
Non-Executive Director,Non-Executive Chairman
Mr Masterson has two decades of experience in the pharmaceutical and healthcare sectors. He began his career with Johnson & Johnson before joining Abbott Laboratories (NYSE: ABT) where he held senior positions. Mark also held the role of CEO with I-MED. Following the acquisition of I-MED, he was appointed Chairman of Medicines Australia.
|Mr Akash Bedi||Non-Executive Director||Jul 2019||
Mr Akash Bedi
Mr Bedi is Group Senior Director of Strategy and Corporate Affairs at H&H Group. He is based in Hong Kong and is responsible for leading H&H Group's strategy and business development including mergers and acquisitions, and strategic investments for NewH2. He has experience in investing in global start-ups and companies with technologies and businesses that are of strategic importance to H&H Group. Akash has experience in multicultural and global environments. Prior to joining H&H Group, he was a Director of Global Consumer and Retail for HSBC for over a decade. During this time he worked on a number of acquisitions in North America, London and Asia. He is Director of Else Nutrition Holdings, Inc.
|Mr Stephen Kelly||Company Secretary||Sep 2018|
|Mr George Livery||Non-Executive Director||Sep 2018||
Mr George Livery
Mr Livery has over 25 years' experience in senior roles domestically and internationally. His last seven years as director of strategy and corporate development at Swisse Wellness Group. In addition, George's executive experience is in positions across multiple other industries including the role of chief executive officer at Village Cinemas Australia, chief operating officer of Village International, commercial director at Hoyts Limited, and director of operations and marketing (non-academic services) at the University of Sydney. George is migration agent, not- for-profit advisor, corporate board strategist, investor and mentor.
|Mr Simon Thomas O'Loughlin||Non-Executive Director||Oct 2016||
Mr Simon Thomas O'Loughlin
Mr O'Loughlin is the founder of O'Loughlins Lawyers. He has experience in the corporate and commercial law fields while practising in Sydney and Adelaide. Simon has experience and involvement with companies in the industrial and resources sectors. He is a former Chairman of the Taxation Institute of Australia (SA Division) and Save the Children Fund (SA Division). He is Director of Chesser Resources Limited, Petratherm Limited, Kibaran Resources Limited, Food Revolution Group Limited, Goldminex Limited, Oklo Resources Limited, Crest Minerals Limited, Reproductive Health Science Limited, King Solomon Mines Limited, Lawson Gold Limited, Gooroo Ventures Limited, ARC Exploration Limited and WCP Resources Limited.
|Ms Joanne (Jo) Patterson||Chief Executive Officer,Executive Director||Oct 2016||
Ms Joanne (Jo) Patterson
Chief Executive Officer,Executive Director
Ms Patterson has over 20 years' experience in business and corporate strategy in Australia and international markets. She has developed a number of businesses from start-up as well as driving established organisations towards growth and merger trajectories. Jo has held multiple CEO and Managing Director roles over her career.
|Craig Weller||Chief Operating Officer||N/A|
The current holdings of BOD directors.
|Director||Last Notice||Direct Shares||Indirect Shares||Options||Convertibles|
|Johannes (Hanno) Cappon||20/07/2021||0||N/A||N/A||N/A|
|Joanne (Jo) Patterson||30/06/2020||N/A||6,550,000||N/A||N/A|
A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.
Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.
|Name||Last Notice||Total Shares||Shares Held (%)|
|Noir Ted Pty Ltd||30/09/2020||4,852,329||5.31|
|Health and Happiness (H and H) Hong Kong Limited||30/09/2020||14,864,865||16.27|
|Health And Beauty Enterprise Pty Limited||30/09/2020||6,550,000||7.17|
|SG Hiscock & Company Limited||12/08/2021||10,201,728||9.64|
12 month transaction history compiled from ASX announcements.
|Date||Name||Bought||Previous %||New %|
|12-08-21||SG Hiscock & Company Limited||2,341,520||8.60||9.64|
12 month transaction history compiled from ASX announcements.
No sell transactions reported by Substantial Shareholders in the past 12 months.
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.